Heron Neutron Medical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	5.53	-	0.24	-
Cost of Revenue	26.5	3.59	0.11	-
Gross Profit	-20.97	-3.59	0.13	-
Selling, General & Admin	164.77	82.02	44.79	36.23
Research & Development	295.33	173.39	84.85	51.57
Operating Expenses	460.1	255.41	129.64	87.8
Operating Income	-481.07	-259	-129.51	-87.8
Interest Expense	-0.14	-0.18	-0.24	-0.28
Interest & Investment Income	9.62	5.72	2.12	0.1
Currency Exchange Gain (Loss)	1.21	0.43	-0.19	0.48
Other Non Operating Income (Expenses)	-0.22	-	0.94	-
EBT Excluding Unusual Items	-470.61	-253.03	-126.88	-87.49
Gain (Loss) on Sale of Investments	-	-	0.49	1.31
Gain (Loss) on Sale of Assets	-	-7.05	-	-
Pretax Income	-470.61	-260.08	-126.39	-86.18
Net Income	-470.61	-260.08	-126.39	-86.18
Net Income to Common	-470.61	-260.08	-126.39	-86.18
Shares Outstanding (Basic)	141	128	107	76
Shares Outstanding (Diluted)	141	128	107	76
Shares Change (YoY)	16.38%	19.11%	40.45%	-
EPS (Basic)	-3.34	-2.04	-1.18	-1.13
EPS (Diluted)	-3.34	-2.04	-1.18	-1.13
Free Cash Flow	-465.37	-302.19	-110.76	-173.14
Free Cash Flow Per Share	-3.30	-2.37	-1.03	-2.27
Gross Margin	-	-	54.20%	-
Operating Margin	-8705.52%	-	-54415.97%	-
Profit Margin	-8516.20%	-	-53105.04%	-
Free Cash Flow Margin	-8421.48%	-	-46536.13%	-
EBITDA	-457.81	-242.89	-119.36	-78.91
D&A For EBITDA	23.25	16.11	10.15	8.89
EBIT	-481.07	-259	-129.51	-87.8
Advertising Expenses	-	3.24	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.